PERVI-FUS

PERVI-FUS is an investigational personalized peptide vaccine developed by the University Hospital Tübingen (Universitätsklinikum Tübingen) for the treatment of fusion-gene driven sarcomas, including Ewing sarcoma, alveolar rhabdomyosarcoma, and synovial sarcoma. The vaccine is designed to elicit a T-cell mediated immune response against tumor-specific neoantigens derived from the unique junction sequences of chromosomal translocation-induced fusion proteins, such as EWS-FLI1, PAX3-FOXO1, or SS18-SSX. By targeting these junction sequences, which are absent in healthy tissue, the therapy aims to provide a highly specific immunotherapy. The vaccine is typically formulated with the novel lipopeptide adjuvant XS15 (a TLR1/2 ligand) emulsified in Montanide ISA 51 VG to enhance the induction of cytotoxic CD8+ and helper CD4+ T cells. It is currently being evaluated in Phase 1 clinical trials to assess safety and immunogenicity in patients with refractory or high-risk sarcomas.

Other names

Personalized fusion-peptide vaccine